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Abstract 
The interactions of irbesartan (IRB) and irbesartan±2-hydroxypropyl-ȕ-
cyclodextrin (HP-ȕ-CD) complex with Dipalmitoyl Phosphatidylcholine (DPPC) 
bilayers have been explored utilizing an array of biophysical techniques ranging 
from Differential Scanning Calorimetry (DSC), Small angle X-ray Scattering 
(SAXS), ESI Mass-Spectrometry (ESI-MS) and solid state Nuclear Magnetic 
Resonance (ssNMR). Molecular Dynamics (MD) calculations have been also 
conducted to complement the experimental results. Irbesartan was found to be 
embedded in the lipid membrane core and to affect the phase transition properties 
of the DPPC bilayers. SAXS studies revealed that irbesartan alone does not 
display perfect solvation since some coexisting irbesartan crystallites are present. 
In its complexed form IRB gets fully solvated in the membranes showing that 
encapsulation of IRB in HP-ȕ-CD may have beneficial effects in the ADME 
properties of this drug. MD experiments revealed the topological and orientational 
integration of irbesartan into the phospholipid bilayer being placed at about 1 nm 
from the membrane centre. 
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1. Introduction 
Angiotensin II type 1 receptor (AT1R) blockers (ARBs) are recently developed 
and marketed drugs. These compounds are structural derivatives of the prototype 
drug losartan and thus belong to the molecular class of sartans. Sartans bear 
preferentially: (i) a biphenyl ring in which an acidic moiety is attached; (ii) a 
single or condensed heterocyclic ring and (iii) a hydrophobic group attached to the 
heterocycle system. It has been proposed that their molecular mechanism of action 
may involve their insertion and diffusion through lipid bilayers before reaching the 
AT1R [1-3]. 
Although, this class of drugs operate through inhibiting the detrimental action of 
the octapeptide hormone angiotensin II (Ang II) in pathogenic states, each sartan 
has a distinct pharmacological profile. This profile is influenced by various 
properties such as absorption, distribution, half life, dose response and level of 
AngII antagonism. Taking these properties into account, irbesartan (IRB) (Fig. 1) 
offers various advantages, in comparison to the other AT1R antagonists. These 
advantages are outlined as follows: (i) IRB is well absorbed; (ii) it does not require 
biotransformation to an active metabolite to exert its antihypertensive activity; (iii) 
it offers a large volume of distribution; (iv) it has a half-life that is sufficient to 
allow single-daily dosing; (v) it is associated with a strong and consistent dose-
response; (vi) it possesses a statistically superior binding affinity, in an inhibitory 
mode, for AT1R, with respect to the majority of ARBs. Adams and Trudeau claim 
that these pharmacological differences may rationalize the clinical superiority of 
IRB as compared with, for instance, the prototype molecule losartan [4]. 
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Since AT1R antagonists suffer from low aqueous solubility, different bilayer 
pharmaceutical formulations have been patented to overcome this disadvantage 
[5]. Another way to enhance their low solubility is through formation of inclusion 
complexes with cyclodextrins (CD). The optimum CD inclusion complex with 
IRB was found to be 10% (w/v) and the solubility of ionized IRB/Ȗ-CD complex 
at pH = 7.2 was shown to be three fold greater than that of the unionized complex 
at pH = 4.3 [6]. In addition, IRB flux via semipermeable membranes increased 
with increasing Ȗ-CD concentration at both pH values [6]. Hirlekar and Kadam 
also found out that complexation of IRB with ȕ-CD enhances the solubility by 
72.5% and increases more than three times its dissolution rate [7]. 
Molecular dynamics experiments have been performed with ȕ-CD located either 
outside or inside lipid bilayers [8]. It was found that ȕ-CD passively diffuses into 
the lipid bilayer by pointing its wide secondary hydroxyl rim towards the lipid 
polar groups and then remains at the phosphate and glycerol-ester groups, where it 
forms hydrogen bonds. The translocation of ȕ-CD deeply inside the hydrophobic 
region of the lipid bilayer is unfavourable [8]. In a recent review by Gharib et al. it 
was reported that the encapsulation efficiency of liposomes for hydrophobic drugs 
was improved for drugs being  primarily hosted in cyclodextrins [9].  
These findings motivated us to explore the capacity of incorporation and 
perturbation of IRB in lipid bilayers alone or in a complex form with 2-
hydroxypropyl-ȕ-cyclodextrin (HP-ȕ-CD). Particularly, our objective was to shed 
light on the following points: (a) Can IRB be released from cyclodextrin when it is 
in the lipid bilayers? (b) If the IRB-HP-ȕ-CD complex is delivered from the 
aqueous phase, is it still possible for IRB to be released in the lipid bilayers and 
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behave dynamically in an identical way? (c) If its dynamic behavior is different, 
what is the driving force generating these alterations? The two different IRB 
preparations used are illustrated in Fig. 2. 
As the model membrane we utilized dipalmitoyl phosphatidylcholine (DPPC) 
(Fig. 1) since it is commonly used as a simple model membrane system mimicking 
the plasma bilayers of eukaryotic cells [10]. In a recent review it has also been 
reported that DPPC is one of the most commonly used phospholipids in the 
preparation of liposomes for entrapping CD inclusion complexes [9]. Cyclodextrin 
was used since it is known to promote the drug transport to its active site and 
therefore increases its pharmacological potential [6, 11-14]. We specifically 
selected, herein, 2-hydroxypropyl-ȕ-cyclodextrin (HP-ȕ-CD) (Fig. 1), since it has 
been reported to be devoid of any toxicity [15-17]. To characterize these 
complexes and to understand the nature of these interactions, we applied a 
combined array of biophysical techniques consisting of Differential Scanning 
Calorimetry (DSC), SI Mass Spectrometry (ESI-MS), Small Angle X-ray 
Scattering (SAXS), solid state Nuclear Magnetic Resonance (ssNMR) and 
Molecular Dynamics (MD). To our knowledge this is the first attempt to compare 
the topology and associated effects of a drug in lipid bilayers both in its 
encapsulated with cyclodextrin form and in its unencapsulated form. 
The obtained results do not only provide information regarding the mode of action 
of IRB at molecular level, but also project insights on new drug delivery routes 
that can potentially offer optimized ADME for this drug [6, 10-14]. 
 
2. Materials and Methods 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
 
 
2.1. Materials 
IRB was kindly provided by Prof. M. Koupparis. DPPC was purchased from 
Avanti Polar Lipids Inc. (Alabaster, AL). Deuterium depleted water and HP-ȕ-CD 
were purchased from Sigma Aldrich (St. Louis, MO). 
2.1.1. Sample preparation 
Preparation of the IRB±HP-ȕ-CD lyophilized complex: A freeze-drying procedure 
was applied for the preparation of IRB±HP-ȕ-CD lyophilized product. For the 
preparation of IRB±HP-ȕ-CD aqueous solutions for freeze-drying in a molar ratio 
of 1:2, the neutralization method was used [18]. More specifically, 0.060 g of 
irbersartan and 0.408 g of HP-ȕ-CD were weighed accurately, transferred in a 100 
mL beaker and suspended with 50 mL of water. Small amounts of ammonium 
hydroxide were then added under continuous stirring and pH monitoring until 
complete dissolution and pH adjustment to a value between 9 and 10 have been 
obtained. The resulting solution at molar ratio of 1:2 was thereafter frozen at -80 
oC and freeze-dried using a Kryodos-50 model Telstar lyophilizer.  
Preparation of liposome mixture: DPPC and IRB stock solutions were prepared by 
dissolving weighted amounts of dry lipid and IRB powder in chloroform. The drug 
concentrations used were x = 0.05 (5 mol%) or x=0.2 (20 mol%). Appropriate 
amounts of drug in a pure or complexed form with HP-ȕ-CD was used in the 
mixtures. The organic DPPC/IRB, or DPPC/complex IRB±HP-ȕ-CD were then 
evaporated at room temperature under a gentle stream of nitrogen and thereafter 
placed under vacuum for 12 hours in order to form a thin lipid film at the bottom 
of glass vials. The obtained mixtures were then fully hydrated (50% wt/wt 
deuterium depleted water) in order to achieve multilamellar vesicles (MLVs). 
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Alternatively, complexed IRB±HP-ȕ-CD compounds were added to the aqueous 
phase of readily formed DPPC MLVs dispersions (see Fig. 1). 
2.2. Methods 
2.2.1. Differential scanning calorimetry 
 The  prepared samples for DSC were transferred to stainless steel capsules 
obtained from Perkin-Elmer and sealed. Thermal scans were obtained on a ȉǹ 
instrument MDSC Model 2910 (De, USA). All samples were scanned from 10 to 
60 °C at least three times until identical thermal scans were obtained using a 
scanning rate of 2.5 °C/min. The temperature scale of the calorimeter was 
calibrated using indium (Tm = 156.6 °C) and DPPC bilayers (Tm = 41.2 °C). The 
following diagnostic parameters were used for the study of drug to membrane 
interactions: Tm (maximum position of the recorded heat capacity), Tonset (the 
starting temperature of the phase transition) and the respective parameters 
concerning the pre-transition. The area under the peak represents the enthalpy 
FKDQJHGXULQJWKHWUDQVLWLRQǻǾ). The mean values of ǻǾ of three identical scans 
were tabulated. The IRB concentrations used for the different experiments were 5, 
10 and 20 mol%. 
2.2.2. Solid-state 13C CP/MAS NMR spectroscopy 
  
13C cross polarization/magic-angle spinning (13C CP/MAS) solid-state NMR 
spectra were recorded on a Varian 600 MHz spectrometers equipped with a 3.2 
mm HX MAS probe. Approximately 20 mg of each sample was packed tightly 
into a zirconia rotor and spun at 5 kHz. The duration of the CP block in the 
CP/MAS experiment was 5 ms, repetition delay between scans was 2 s, and 
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number of scans was 400. The 13C chemical shift axis was referenced to 
tetramethylsilane.  
For the sample DPPC/HP-ȕ-CD (x=0.20) 13C CP/MAS and MAS spectra were 
recorded at sample rotation frequency of 15 kHz. The spectra were recorded on a 
Bruker 600 MHz spectrometer equipped with a 4 mm HX MAS probe. 
Approximately 50 mg of each sample was packed tightly into a zirconia rotor. 
Cross-polarization was used for 13C excitation using an 80% linear ramp. During 
13C detection, 100 kHz Spinal-64 proton decoupling was applied [19-21]. The 
number of scans used in the experiment was 1000.   
2.2.3. X-ray diffraction experiments 
Small angle X-ray scattering (SAXS) measurements were performed with a high-
flux SAXSess camera (Anton Paar, Graz, Austria) connected to a Debyeflex 3003 
X-ray generator (GE-Electric, Germany), operating at 40 kV and 50 mA with a 
sealed-tube Cu anode. The Goebel-mirror focused and Kratky-slit collimated X-
ray beam was line shaped (17 mm horizontal dimension at the sample) and 
scattered radiation was measured in the transmission mode and recorded by a one-
dimensional MYTHEN-1k microstrip solid-state detector (Dectris Switzerland), 
within a q-range (with q being the magnitude of the scattering vector) of 0.01 to 
0.5 Å-1. Using Cu KĮ radiation of wavelength 1.54 Å and a sample-to-detector 
distance of 307 mm this FRUUHVSRQGVWRDWRWDOșUHJLRQRIWRDSSO\LQJ
the conversion q [A-1] = ʌVLQșȜZLWKșEHLQJWKHVFDWWHULQJDQJOHZLWKUHVSHFW
WRWKHLQFLGHQWEHDPDQGȜWKHZDYHOHQJWKRIWKH;-rays. Samples were filled into 
a 1 mm (diameter) reusable quartz capillary (wall thickness of 10 µm) with 
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vacuum-tight sealing screw-caps at both ends. All measurements of the samples in 
the capillary were done in  vacuum and at the respective temperatures with an 
exposure time of 10 min at each temperature step in a heating scan (20° to 50°C in 
5° intervals with 10 min equilibration). 
2.2.4. Molecular dynamics 
The CHARMM 36 force field [22, 23] was employed for the simulation of a fully 
hydrated DPPC bilayer at the atomistic level while the water phase was described 
by the well-known transferable intermolecular potential 3 point (TIP3P) model 
[24]. As far as the initial configuration of the bilayer is concerned, it was 
downloaded from the web-page of the Laboratory of Molecular and 
Thermodynamic Modeling at the University of Maryland. The topology files for 
IRB and the CD derivative were created with the SwissParam server program [25]. 
The latter choice is justified as follows: SwissParam provides topology files in 
GROMACS format based on Merck molecular force field (MMFF) in a functional 
form that is in compatibility with the CHARMM force field. It should also be 
mentioned that MMFF reproduces accurately bond lengths, bond angles and 
vibrational frequencies in comparsion with experimental data as well as treating 
correctly conformational energetics [26]. Another reason for choosing the 
SwissParam server was the extensive number of successful tests for organic 
molecules reported in references [25, 26]. Also, according to reference 25, further 
optimization of the force-field parameters may be needed for highly accurate 
calculations of complex organic molecules. All molecular dynamics (MD) 
simulations were conducted with the GROMACS 5.1.1 package [27] in the NPZAT 
ensemble with a constant area, A, being equal to 0.64 nm2/lipid, while the 
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equations of motion were integrated with a time step of 1 fs. The temperature and 
pressure along the Z-axis were kept constant at 323K and 1bar, respectively, by 
employing the Berendsen thermostat and barostat [28]. Long-range electrostatic 
interactions were treated with the particle mesh Ewald (PME) method [29], while 
Lennard-Jones interactions were calculated using a 1.2 nm cut-off radius. The 
forces were smoothly switched to zero between a distance of rvdw-switch=1.0 nm and 
the previously-mentioned cut-off radius by applying the force-switch option of 
GROMACS package. Two different concentrations of IRB molecules were 
simulated in the lipid membrane, i.e.: 1.4 mol.%, 12.2mol.%. The complex formed 
by IRB and HP-ȕ-CD was created in an aqueous phase containing 13284 water 
molecules. The membrane under study contained 72 DPPC molecules in contact 
with 2162 water molecules. These two systems were initially energy-minimized 
using the steepest descent method, and subsequently MD simulations were 
conducted for 0.5 ȝs. The same membrane was employed in the presence of IRB±
HP-ȕ-CD, but in this case the aqueous phase contained 3604 water molecules. The 
total duration of the IRB±HP-ȕ-CD±DPPC MD simulation was 1ȝs. In addition, a 
set of 29 umbrella sampling simulations were performed for the computation of 
the potential of mean force (PMF) of the IRB from lipid to water phase by 
employing the weighted histogram analysis method (WHAM) [30]. In particular, 
the Z-axis was selected to be the reaction coordinate, ȗ, the bilayer centre 
corresponding to the value ȗ=0.0 nm. The duration of the biasing simulations was 
85 ns, of which the first 35 ns were regarded as equilibration and therefore were 
discarded. The protocol applied for the computation of PMF was according to that 
of the reference 39 and references therein.  
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2.2.5 ESI-MS measurements 
7KH(924(OLWH(5/&-TQ system, triple quadrupole mass spectrometer was 
used to perform full scan analysis of the HP-ȕ-CD and IRB±HP-ȕ-CD complex. 
Ǽach of them (0.1mg) was diluted in distilled H2O (LC-MS grade, Fisher) and 
injected directly to the spectrometer. The measurement was performed in negative 
ionization mode, using an ESI probe. Spray voltage (-) was set to 4000 V, heated 
probe gas flow to 0 units, heated probe temperature at 40 °C, cone gas flow to 20 
units, cone temperature at 300 °C and nebulizer gas flow to 20 units. Results were 
collected through the MSWS software, provided by Bruker. 
 
3. Results and Discussion 
3.1 Differential scanning calorimetry 
Pure fully hydrated DPPC bilayers (Fig. SF1A, Table 1) show two characteristic 
endothermic peaks, the pre- and the main transition, respectively. Below the 
pretransition the DPPC molecules form the well-organized lamellar gel phase, Lȕƍ, 
while above the main transition temperature a fluid lamellar phase, LĮ, is apparent. 
An intermediate phase, Pȕƍ, is also observed, in which the bilayers are modulated 
by a periodic ripple (ripple phase) [31]. The recorded transition temperatures and 
enthalpies are in good agreement with literature [32]. 
The presence of 20% mol of IRB results in a reduction of the Tm and narrowing of 
the transition width of the main phase transition (Fig. SF1B). IRB abolishes the 
pre-transition indicating a strong effect on the head-group region of lipid bilayers, 
while it does not affect ǻǾ considerably (Table 1). 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
 
 
 
HP-ȕ-CD does not cause significant changes on DPPC bilayers (Fig. SF1C). Both 
pre-transition and main phase transition are conserved, however, shifted to lower 
WHPSHUDWXUHVDQGWKHHQWKDOS\ǻǾ, is reduced too. When the complex is provided 
from the aqueous phase to the readily formed DPPC MLVs, then m was observed 
about 2 °C lower (Fig. SF1'DQGDOVRǻǾ of this sample was determined to be 
lower than that of pure DPPC bilayers. 
MLV derived after hydration of DPPC and IRB±HP-ȕ-CD complex in the lipid 
film form displayed in the DSC scan 1.3 °C lower Tm as compared to pure DPPC 
bilayers and similar ǻǾ (Fig. SF1E). The above thermal profiles show that DPPC 
bilayers containing IRB±HP-ȕ-CD complex provided outside or included inside 
during the preparation that IRB is released and perturbs the lipid bilayers.  
 
3.2. Small angle X-ray scattering 
DPPC bilayers in the gel phase show four distinct diffraction orders indicating a 
high stacking order of the phospholipid membranes. At temperatures between the 
pretransition and main transition corrugated bilayers with a periodic ripple and 
hexagonal chain packing are formed. This is seen as a broadening of the 
reflections. In the liquid crystalline phase, a sharpening of the peaks and an 
increase in intensity is seen, typical for the reformation of planar lipid bilayers 
(Fig. 3A). 
As seen in the relatively broad diffraction peaks the stacking of the DPPC/IRB 
bilayers is less ordered as compared to pure DPPC bilayers (Fig. 3B). While in the 
gel-phase regime (20-40 °C) only a slightly higher repeat is apparent (Figure 4), in 
the liquid crystalline phase only spatially uncorrelated membranes are observed 
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(45-55 °C), i.e. the bilayers unbind. Further, IRB suppresses the formation of the 
ripple phase as confirmed from the DSC measurements. Most strikingly, above the 
main transition temperature only diffuse scattering arising from spatially 
uncorrelated bilayers is observed. A consistent explanation would be that the 
incorporation of IRB in the LĮ phase leads to an increase in fluidization of the 
hydrocarbon chains causing stronger bilayer undulations, and finally provokes the 
unbinding of the membranes. Although IRB strongly interacts with DPPC bilayers 
over the entire studied temperature range, we note that IRB is not totally solvated 
in the bilayers, since a strong diffraction peak at q = 0.335 Å-1 is clearly visible 
throughout the entire temperature range (marked with * in Fig. 3B). This 
diffraction peak stems most probably from precipitated IRB aggregating in the 
crystal A form [33]. 
The incorporation of HP-ȕ-CD in DPPC bilayers does not suppress any phase 
formation, but a broadening of the diffraction peaks is observed in all three phases 
(Fig. 3C). This indicates that the stacking of the lipid bilayers is not as ordered as 
with pure DPPC bilayers. In accordance to the DSC data, both the pretransition 
and main transition are lowered by a few degrees, and it is tempting to assume that 
the HP-ȕ-CD incorporation decreases the packing density of the lipids. This would 
in turn lead bilayers with a decreased bending modulus, and hence explain the 
reduced quasi long-range order of the membrane stacking as confirmed by the 
broadening of the diffraction peaks. 
When the IRB±HP-ȕ-CD complex is added to the excess of water layer, and 
subsequently interacts with the DPPC bilayers, only in the Lȕ¶ phase broad 
diffraction peaks are apparent (Fig. 3D: 20-25 °C). From 30 °C onwards merely 
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diffuse scattering arising from spatially uncorrelated membranes are observed. 
When the IRB±HP-ȕ-CD complex was in dry lipid film mixture with DPPC and 
then hydrated, the fluidization effect of the membranes is maximized as it can be 
observed by the increase breadth of the spectra profiles (Fig. 3E). 
3.3. Solid state NMR spectroscopy 
3.3.1. HP-ȕ-CD in DPPC bilayers 
13C CP/MAS experiments using phospholipid bilayers both in gel and liquid 
crystalline phases have been used to examine the effect of HP-ȕ-CD on DPPC 
bilayers. Two kinds of experiments have been performed at ambient temperature: 
(a) In the first experiment HP-ȕ-CD has been co-dissolved with DPPC in 
chloroform, evaporated, dried and hydrated to form fully hydrated multilamellar 
vesicles (Figure 2A); (b) In the second experiment HP-ȕ-CD was added to the 
aqueous phase of DPPC prepared multilamellar vesicles (Figure 2B). The obtained 
spectra showed almost no additional peaks attributed to HP-ȕ-CD. As in both 
methods the spectra were identical, we proceeded obtaining 13C CP/MAS spectra 
using the first methodology at three temperatures (25-45 °C) to cover all 
mesomorphic states of DPPC bilayers. Again, the peaks of HP-ȕ-CD were barely 
observable (Figure 5 and Fig. SF2). The absence of cross polarization between 
HP-ȕ-CD and phospholipid DPPC presumably shows that the former molecule sits 
on the surface of the lipid bilayers and that the distances between the 1H and 13C 
nuclei of the two species are thus sufficiently large or that the dynamics of the HP-
ȕ-CD is sufficiently fast, so that the 1H-13C (residual) dipolar interaction is 
practicaly negligible. 13C MAS experiments confirmed this preposition as the 
peaks attributed to (HP-ȕ-CD) are eminent at 15 °C (Figure 6).  
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These results are in agreement with those of DSC, which showed only small effect 
of HP-ȕ-CD on DPPC bilayers. Small effect of HP-ȕ-CD on DPPC bilayers were 
also reported previously. HP-ȕ-CD was among the least perturbing CDs used in 
the studies performed by Nishuo et al. [34, 35]. 
3.3.2. Irbesartan in DPPC bilayers 
 DPPC bilayers containing IRB at the three different temperatures of 25 °C, 35 °C 
and 45 °C, covering all mesomorphic states of the phospholipid bilayers, were also 
inspected by NMR. As it can be observed from Tables ST1 and ST2 the chemical 
shifts of the carbons presenting the phospholipid bilayers have not been modified 
significantly due to the presence of the drug. Additional peaks due to the drug 
attributed to its flexible and rigid segments have been observed. The aromatic 
region of the drug consists of peaks characterized by increased linewidth, an 
indication that this region of the lipid bilayers is squeezed into the lipid bilayers 
with restrained flexibility. C31 and C30 belonging to the butyl chain of the drug 
are clearly seen in all temperature range (25-45 °C) [36]. Thus, the butyl chain of 
IRB is embedded in a more flexible hydrophobic core of phospholipid bilayers 
compared to the aromatic region. However, the peaks are still broad designating 
restraint in the lipid core. C4 is also observable at the temperature range in which 
the experiments were conducted. This evidence that the cyclopentyl ring of 1,3-
diazaspiro[4.4]non-1-en-4-one is embedded deep in the hydrophobic core of the 
lipid bilayers, a more flexible segment. C6-C9 carbons of the cyclopentyl ring are 
restrained into the lipid bilayers and do not appear in the spectra. Another reason 
for not observing these peaks may be their coincidence with the peaks of 
phospholipid aliphatic area. The amide carbonyl group of 1,3-diazaspiro[4.4]non-
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1-en-4-one is clearly discernible at 25 °C but not observable at 35 °C and 45 °C 
showing its dependence on the fluidity of the lipid bilayers (Figure 5, Figure SF2). 
3.3.3. Irbesartan complex with HP-ȕ-CD in DPPC bilayers 
Two kinds of experiments have been conducted. In the first experiment the 
complex is included as a mixture with DPPC and subsequently hydrated (Figure 
2A) In the second preparation, the complex of the drug was added from outside 
(Figure 2B).  
In the first kind of experiments using cross polarization and temperature range of 
25-45 °C signals of the drug molecule are very broad (Fig. 5 and Fig. SF2). Peaks 
of HP-ȕ-CD are not observed showing again that cyclodextrin is located at the 
surface of the lipid bilayers. When MAS experiment was performed at 45 °C, thus 
without using cross polarization (see supporting information), peaks attributed to 
cyclodextrin are clearly seen proving again that cyclodextrin is localized on the 
surface of the lipids bilayers. In the second kind of experiments using again cross 
polarization and temperature range of 25-45 °C the signals of the drug molecule 
are very broad.   
 
3.4. Molecular dynamics 
This section begins with the detailed analysis of the PMF of IRB from lipid to 
water phase, which is depicted in SF3(a). At large distances, the curve in question 
approaches a constant value corresponding to the value in the water phase. 
Regarding the position of the minimum, it is located approximately 1.0 nm from 
the bilayer center, while the free-energy barrier for a drug molecule to jump from 
one leaflet of the membrane to the opposite one is 28.5kJ/mol. This rather high 
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value indicates that crossing events are not easily realizable and may not be 
observed during MD simulations of duration on the order of hundreds of ns. 
Moreover, one can compute from such a curve the free-energy difference of 
partitioning into the membrane as the difference between the PMF value at large 
distances (>2.5 nm) and the PMF value at the minimum. This free-energy 
difference is approximately 33.5 kJ/mol. Another interesting feature of the curve 
of SF3(a) is the existence of a linear region (1.5-2.3 nm) indicating a large 
attractive force toward the interior of the lipid membrane. The slope of this linear 
region is estimated as 30.5 kJ/mol/nm by applying a linear least-squares fit. In 
addition, an analysis of errors was applied in the computed PMF. This analysis 
was based on the WHAM utility of GROMACS which is described in detail in 
reference 30; the statistical uncertainty, given by the standard deviation [30], is 
estimated by using boostrap analysis [37]. More specifically, the errors in the PMF 
were computed as a function of the selected reaction coordinate. These errors are 
visualized as errorbars in Figure SF3(b) with all errorbars being less than 2.4 
kJ/mol. An interesting study of technical issues (e.g. dependence of errors on the 
position along the reaction coordinate) of umbrella sampling and metadynamics is 
that of reference [38]. As far as the unbiased MD simulations are concerned, one 
IRB molecule was initially placed in the water phase and the whole system was 
energy minimized using the steepest descent method [28]. A graphical 
representation of this system is provided in Figure 7A, in which the IRB is 
visualized with green contour after its insertion into the lipid phase. SF4(a) shows 
the temporal evolution of the Z-coordinate of the IRB center of mass (green color) 
along with the Z-coordinates of DPPC phosphorus centers of mass (black color) 
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for the two leaflets of the lipid membrane. It is observed that, after nearly 11ns of 
MD simulation, the IRB molecule was inserted in the bilayer and thus during this 
time interval the green dots are not found in the intermediate area delimited by the 
black curves. In the rest of this simulation, no crossing events were recorded and 
this means that the free-energy barrier (see Figure SF3(a)) for hopping between 
the two leaflets was not overcome. Moreover, the IRB center of mass is fluctuating 
around 1nm from the bilayer center, as expected from the minimum value of the 
PMF. Having established that IRB prefers being inserted in the bilayer, a higher 
concentration (12.2%) was also simulated by placing the drug molecules inside the 
hydrophobic core of the lipid phase. Again the NPzAT ensemble was used, with the 
area per lipid set to 0.64nm2. This choice is justified by experimental results 
presented in an older study concerning the candesartan cilexetil, another molecule 
belonging to the class of sartans [39]. More specifically, the area per lipid up to 
concentrations of 12% varies from 0.645 to 0.630 nm2. The temporal evolution of 
the Z-coordinate of the IRB center of mass, in the case of the highest 
concentration, is depicted in SF4(b) with each drug molecule being visualized by a 
different color. Again no crossing event was observed during the 0.5ȝs of the 
production run. Moreover, the density profiles along the Z-axis for the same 
system are provided in Figure 7B. The drugs are distributed symmetrically in the 
two leaflets, whereas the peak values are in accordance with the PMF. One 
representative conformation of IRB inside the bilayer, as estimated by applying a 
clustering algorithm that is available in the USCF chimera software [40], is given 
in Figure 8. The axes of the simulation box are also included in the 
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aforementioned figure for a better understanding of the relative position of the IRB 
with respect to the characteristic direction of the Z-axis.  
Now we turn our attention to the formation of the complex IRB±HP-ȕ-CD. To this 
end, IRB and the CD derivative were placed in a water phase described by the 
TIP3P model at an initial distance greater than 2.0 nm. Our aim was the 
spontaneous creation of the complex under the employed force-field (see also the 
simulation details section). Indeed, the IRB±HP-ȕ-CD complex was created within 
the first ten nanoseconds of a 140 ns MD simulation. After the formation of the 
complex and making use of the pairdist utility of GROMACS, the distance 
between the centers of mass of the two molecules in the bound state is 
(0.649±0.004) nm. Next, the last IRB±HP-ȕ-CD configuration of this MD 
simulation was placed in the water phase surrounding the lipid bilayer of 72 DPPC 
molecules. The time evolution of the IRB±HP-ȕ-CD is monitored in terms of the 
Z-coordinate of its two constituent molecules. As seen in SF5, the complex enters 
the membrane after nearly 40 ns of MD simulation. Another interesting conclusion 
from the aforementioned figure is that the IRB is located deeper in the membrane 
with respect to the CD derivative which fluctuates asymmetrically around the 
positions of phosphorus atoms of one DPPC leaflet. A complementary view of this 
system is provided in Figure 7D in which density profiles along the Z-axis of 
various components are depicted with different colours. This diagram is taken 
from the last 0.25 ȝs of the MD simulation and the abscissa is extended to higher 
values in comparison to those of Figure 7B, since an extended water phase is 
employed in this case. The IRB±HP-ȕ-CD density profile is visualized in green 
colour, whilst the profile concerning IRB itself is separately depicted with red 
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colour. ǹ graphical representation of the system under study is given in Figure 7C 
with the CD derivative and IRB shown in black and blue colours, respectively. It 
is also seen from this figure that IRB is oriented towards the interior of the 
membrane and the CD derivative is located at the water-DPPC interface.   
3.5 ESI-Mass spectrometry studies 
To qualitatively asses the species present in the IRB±HP-ȕ-CD complex ESI mass-
spectroscopy was utilized (Fig. 9). This technique has been formerly used to 
monitor weak non-covalent interactions such as the supramolecular interactions of 
HP-ȕ-CD with losartan [41] and progesterone [42].  
Fig. 9A illustrates the mass spectrum of HP-ȕ-CD. In this spectrum a distribution 
of peaks is observed with m/z between 1400.00 and 1650.00, with the following 
three peaks with m/z 1447.70, 1483.80 and 1541.7 that have been used in the 
characterization of the complex that follows. Such broad distribution has been 
attributed due to the presence of a mixture of different cyclodextrins bearing 
different degree of substitution in HP-ȕ-CD [41]. In Fig. 9B the ESI-MS spectrum 
of the IRB±HP-ȕ-CD complex is presented. At m/z values localized between 1800 
and 2000 three peaks are observed, 1853.10, 1911.40 and 1968.70, relating to 
three types of inclusion compounds with stoichiometry 1:1. The relevant result 
could be attributed to the formation of a stable complex driven by hydrophobic 
interactions as supported by the complementary techniques used in this work, 
similar to the case of the reported complex of losartan with HP-ȕ-CD REF 41. 
This is in contrast to the case of the reported complex of progesterone with ȕ-CD 
or HP-ȕ-CD where different and higher complex ratios could be monitored [42]. 
These higher complex ratios have been hypothesized to be formed due to 
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nonspecific interactions of ȕ-CD or HP-ȕ-CD with progesterone rather than 
hydrophobic inclusion. 
 
4. Conclusions 
IRB is a marketed drug with a well known antihypertensive activity and other 
beneficial effects. Its mode of action may be strongly related to its membrane 
incorporation and subsequent diffusion to the active site of the AT1R. Due to 
,5%¶V high lipophilicity its formulation with HP-ȕ-CD may improve its 
pharmacological profile. It is therefore of great importance to study its interactions 
with model membranes both in its complexed form with HP-ȕ-CD as also in its 
unencapsulated form. Herein, two formulations have been evaluated: (i) either a 
1:1 complex of HP-ȕ-CD with IRB, as characterized by ESI MS, was added to the 
aqueous phase of the MLV dispersions or (ii) mixed DPPC/IRB±HP-ȕ-CD (4:1) 
complex films were hydrated.  
The thermal changes observed using the macroscopic method of DSC suggest: (a) 
HP-ȕ-CD does not exert strong effect in DPPC bilayers, but it sits on the surface. 
This observation is strongly supported by the microscopic method of ssNMR 
spectroscopy. 13CP/MAS experiments showed no additional peaks due to HP-ȕ-
CD, peaks that were evident when cross polarization was not applied. (b) 
Irbesartan is inserted in DPPC bilayers where it modifies significantly the thermal 
profile of pure DPPC bilayers. MD experiments confirm DSC results and provide 
complementary information on the localization of the molecule. Information on 
the localization of irbesartan in DPPC bilayers is obtained also through ssNMR. 
Clearly, broad peaks of the aromatic segments of irbesartan are observed, 
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signifying that they are intercalating well in the bilayer¶V hydrophobic region and 
this reduces the mobility of the alkyl chains. In addition, all segments of irbesartan 
are intercalated with different mobility as it is shown by the 13CP/MAS 
experiments. X-ray diffraction data also complement results from ssNMR, DSC 
and MD as they show not only strong interactions between irbesartan and DPPC 
bilayers, but also its inability for full solvation. (c) Interestingly, different modes 
of delivery of IRB to model membranes, unencapsulated or IRB±HP-ȕ-CD 
encapsulated, exerted significant differences on the membrane internalization as 
depicted by DSC, solid state NMR spectroscopy, X-ray diffraction and Molecular 
Dynamics. Only in its complexed form IRB gets fully solvated in the membranes, 
whereas the pure IRB/DPPC interactions led to the additional formation of IRB 
crystals. These results highlight that encapsulation of IRB in HP-ȕ-CD may have 
beneficial effects in the ADME properties of this drug. 
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Table legends 
Table 1: Thermal parameters for different DPPC samples studied. 
Samples 
Pretransition 
state 
Transition state 
ǻǾ
(J/g) 
Tpre 
(ºC) 
ǻǾJ/g) Tm (ºC) 
DPPC 6.3 35 41.8 41.2 
DPPC/IRB (80:20)   40.8 39.7 
DPPC/HP-ȕ-CD (80:20) 3.9 33 34.0 39.3 
DPPC/[IRB±HP-ȕ-CD] complex 
added (80:20) 
  38.2 39.3 
DPPC/[IRB±HP-ȕ-CD]   (80:20)   41.0 39.8 
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FIGURES LEGENDS 
Figure 1: Irbesartan, DPPC and 2-Hydroxypropyl-ȕ-Cyclodextrin (HP-ȕ-CD). 
The labeled numbers are used for the structure identification in NMR studies.  
Figure 2: (left) IRB complex with CD during the preparation is within the lipid 
bilayers (right) IRB complex with CD is provided outside from the lipid bilayers. 
These two different preparations potentially can lead to two different ways that 
IRB interacts with lipid bilayers after its release.   
Figure 3: 6ǹȋ6H[SHULPHQWVRQǹSXUH'33&ELOD\HUVǺ'33&IRB bilayers 
(80:20); (C) DPPC/HP-ȕ-CD bilayers (80:20); (D) DPPC MLV dispersion with 
[IRB/HP-ȕ-&'@ FRPSOH[ DGGHG  DQG Ǽ'33&>IRB/HP-ȕ-CD] bilayers 
(80:20). 
Figure 4: D-spacings versus temperature for pure DPPC bilayers (blue circles); 
DPPC/IRB bilayers (80:20) (black triangles); DPPC/HP-ȕ-CD bilayers (80:20) 
(red squares); and DPPC MLV dispersion with [IRB/HP-ȕ-CD] added (80:20) 
(green diamonds). Note, DPPC/[IRB/HP-ȕ-CD] bilayers (80:20) display only 
uncorrelated (unbound) bilayers. 
Figure 5: 13C CP/MAS spectra of the samples used in our studies recorded at 45 
oC and using Bruker 600 MHz spectrometer. Asterisks designate peaks originating 
from HP-ȕ-CD. 
Figure 6: 10 kHz CP (blue) versus red MAS spectrum, at 15 oC of the sample 
DPPC/ HP-ȕ-CD (x=0.20). The MAS spectrum shows additional signals which 
can be assigned to HP-ȕ-CD.   
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Figure 7: A) Snapshot of one IRB molecule in the DPPC bilayer. The green 
contour is employed for a better visualization of the molecule in question. B) 
Density profiles of water, DPPC and IRB molecules (12.2 mol%) along the Z-axis 
which is perpendicular to the two monolayers of the membrane. C) Graphical 
representation of IRB±HP-ȕ-CD in the DPPC membrane in contact with an 
extended water phase. The IRB and CD derivative are depicted with blue and 
black colour, respectively. D) Density profiles of water, DPPC, IRB and IRB±HP-
ȕ-CD along the Z-axis during the last 0.25 ȝs of an MD simulation. 
Figure 8: Representative conformation of IRB in the DPPC bilayer. 
Figure 9. Electrospray mass spectrum in negative ion mode of (A) HP-ȕ-CD and 
(B) IRB±HP-ȕ-CD complex. 
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Figure 2 
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Figure 5. 
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Figure 7 
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Figure 9. 
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Graphical Abstract 
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Highlights 
x Investigation of a drug-cyclodextrin-lipid bilayer system. 
x Irbesartan insertion in DPPC bilayers modifies their thermal profile.  
x MD experiments provide information on the localization of irbesartan in 
DPPC. 
